{
    "references": [
        {
            "bibentry": "Thiesen, HJ, Steinbeck, F, Maruschke, M, Koczan, D, Ziems, B, Hakenberg, OW. Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis, PLoS One, 2017, 12, e0176659, PMID: 28486536",
            "process_entry": "True",
            "doi": "10.1371/journal.pone.0176659",
            "pmid": "28486536",
            "pmcid": "PMC5423597",
            "xmlid": "B1"
        },
        {
            "bibentry": "Ljungberg, B, Bensalah, K, Canfield, S, Dabestani, S, Hofmann, F, Hora, M. EAU guidelines on renal cell carcinoma: 2014 update, Eur Urol, 2015, 67, 913, 924, PMID: 25616710",
            "process_entry": "True",
            "doi": "10.1016/j.eururo.2015.01.005",
            "pmid": "25616710",
            "xmlid": "B2"
        },
        {
            "bibentry": "Young, JR, Coy, H, Douek, M, Lo, P, Sayre, J, Pantuck, AJ. Clear cell renal cell carcinoma: identifying the gain of chromosome 12 on multiphasic MDCT, Abdom Radiol (NY), 2017, 42, 236, 241, PMID: 27519835",
            "process_entry": "True",
            "doi": "10.1007/s00261-016-0868-7",
            "pmid": "27519835",
            "xmlid": "B3"
        },
        {
            "bibentry": "Mehdi, A, Riazalhosseini, Y. Epigenome aberrations: emerging driving factors of the clear cell renal cell carcinoma, Int J Mol Sci, 2017, 18, E1774, PMID: 28812986",
            "process_entry": "True",
            "doi": "10.3390/ijms18081774",
            "pmid": "28812986",
            "pmcid": "PMC5578163",
            "xmlid": "B4"
        },
        {
            "bibentry": "Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2017, CA Cancer J Clin, 2017, 67, 7, 30, PMID: 28055103",
            "process_entry": "True",
            "doi": "10.3322/caac.21387",
            "pmid": "28055103",
            "xmlid": "B5"
        },
        {
            "bibentry": "Drucker, BJ. Renal cell carcinoma: current status and future prospects, Cancer Treat Rev, 2005, 31, 536, 545, PMID: 16236454",
            "process_entry": "True",
            "doi": "10.1016/j.ctrv.2005.07.009",
            "pmid": "16236454",
            "xmlid": "B6"
        },
        {
            "bibentry": "Scélo, G, Brennan, P. The epidemiology of bladder and kidney cancer, Nat Clin Pract Urol, 2007, 4, 205, 217, PMID: 17415353",
            "process_entry": "True",
            "doi": "10.1038/ncpuro0760",
            "pmid": "17415353",
            "xmlid": "B7"
        },
        {
            "bibentry": "Pan, Y, Liu, G, Zhou, F, Su, B, Li, Y. DNA methylation profiles in cancer diagnosis and therapeutics, Clin Exp Med, 2018, 18, 1, 14, PMID: 28752221",
            "process_entry": "True",
            "doi": "10.1007/s10238-017-0467-0",
            "pmid": "28752221",
            "xmlid": "B8"
        },
        {
            "bibentry": "van der Kooi, EL, de Greef, JC, Wohlgemuth, M, Frants, RR, van Asseldonk, RJ, Blom, HJ. No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy, Neuromuscul Disord, 2006, 16, 766, 769, PMID: 17005397",
            "process_entry": "True",
            "doi": "10.1016/j.nmd.2006.08.005",
            "pmid": "17005397",
            "xmlid": "B9"
        },
        {
            "bibentry": "Hao, X, Luo, H, Krawczyk, M, Wei, W, Wang, W, Wang, J. DNA methylation markers for diagnosis and prognosis of common cancers, Proc Natl Acad Sci U S A, 2017, 114, 7414, 7419, PMID: 28652331",
            "process_entry": "True",
            "doi": "10.1073/pnas.1703577114",
            "pmid": "28652331",
            "pmcid": "PMC5514741",
            "xmlid": "B10"
        },
        {
            "bibentry": "Dubrowinskaja, N, Gebauer, K, Peters, I, Hennenlotter, J, Abbas, M, Scherer, R. Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response, Cancer Med, 2014, 3, 300, 309, PMID: 24464810",
            "process_entry": "True",
            "doi": "10.1002/cam4.181",
            "pmid": "24464810",
            "pmcid": "PMC3987080",
            "xmlid": "B11"
        },
        {
            "bibentry": "Wang, L, Gao, W, Hu, F, Xu, Z, Wang, F. MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9, FEBS Lett, 2014, 588, 4527, 4535, PMID: 25281924",
            "process_entry": "True",
            "doi": "10.1016/j.febslet.2014.09.035",
            "pmid": "25281924",
            "xmlid": "B12"
        },
        {
            "bibentry": "Zhang, L, Yan, DL, Yang, F, Wang, DD, Chen, X, Wu, JZ. DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer, Oncotarget, 2017, 8, 45496, 45505, PMID: 28525377",
            "process_entry": "True",
            "doi": "10.18632/oncotarget.17569",
            "pmid": "28525377",
            "pmcid": "PMC5542203",
            "xmlid": "B13"
        },
        {
            "bibentry": "Li, W, Zhang, X, Lu, X, You, L, Song, Y, Luo, Z. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers, Cell Res, 2017, 27, 1243, 1257, PMID: 28925386",
            "process_entry": "True",
            "doi": "10.1038/cr.2017.121",
            "pmid": "28925386",
            "pmcid": "PMC5630683",
            "xmlid": "B14"
        },
        {
            "bibentry": "Jeschke, J, Bizet, M, Desmedt, C, Calonne, E, Dedeurwaerder, S, Garaud, S. DNA methylation-based immune response signature improves patient diagnosis in multiple cancers, J Clin Invest, 2017, 127, 3090, 3102, PMID: 28714863",
            "process_entry": "True",
            "doi": "10.1172/JCI91095",
            "pmid": "28714863",
            "pmcid": "PMC5531413",
            "xmlid": "B15"
        },
        {
            "bibentry": "Zhang, W, Yan, W, You, G, Bao, Z, Wang, Y, Liu, Y. Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP-primary glioblastoma, Cancer Lett, 2013, 328, 120, 125, PMID: 22960273",
            "process_entry": "True",
            "doi": "10.1016/j.canlet.2012.08.033",
            "pmid": "22960273",
            "xmlid": "B16"
        },
        {
            "bibentry": "Shukla, S, Pia Patric, IR, Thinagararjan, S, Srinivasan, S, Mondal, B, Hegde, AS. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus, Cancer Res, 2013, 73, 6563, 6573, PMID: 24078801",
            "process_entry": "True",
            "doi": "10.1158/0008-5472.can-13-0298",
            "pmid": "24078801",
            "xmlid": "B17"
        },
        {
            "bibentry": "Sandoval, J, Mendez-Gonzalez, J, Nadal, E, Chen, G, Carmona, FJ, Sayols, S. A prognostic DNA methylation signature for stage I non-small-cell lung cancer, J Clin Oncol, 2013, 31, 4140, 4147, PMID: 24081945",
            "process_entry": "True",
            "doi": "10.1200/jco.2012.48.5516",
            "pmid": "24081945",
            "xmlid": "B18"
        },
        {
            "bibentry": "Evelönn, EA, Landfors, M, Haider, Z, Köhn, L, Ljungberg, B, Roos, G. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma, BMC Cancer, 2019, 19, 65, PMID: 30642274",
            "process_entry": "True",
            "doi": "10.1186/s12885-019-5291-3",
            "pmid": "30642274",
            "pmcid": "PMC6332661",
            "xmlid": "B19"
        },
        {
            "bibentry": "Peters, I, Dubrowinskaja, N, Hennenlotter, J, Antonopoulos, WI, Von Klot, CAJ, Tezval, H. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients, Oncol Rep, 2018, 40, 3861, 3868, PMID: 30272321",
            "process_entry": "True",
            "doi": "10.3892/or.2018.6732",
            "pmid": "30272321",
            "xmlid": "B20"
        },
        {
            "bibentry": "Dagher, J, Delahunt, B, Rioux-Leclercq, N, Egevad, L, Srigley, JR, Coughlin, G. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading, Histopathology, 2017, 71, 918, 925, PMID: 28718911",
            "process_entry": "True",
            "doi": "10.1111/his.13311",
            "pmid": "28718911",
            "xmlid": "B21"
        },
        {
            "bibentry": "Delahunt, B, Cheville, C, Martignoni, G, Humphrey, PA, Magi-Galluzzi, C, McKenney, J. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters, Am J Surg Pathol, 2013, 37, 1490, 1504, PMID: 24025520",
            "process_entry": "True",
            "doi": "10.1097/pas.0b013e318299f0fb",
            "pmid": "24025520",
            "xmlid": "B22"
        },
        {
            "bibentry": "Cho, HJ, Yu, A, Kim, S, Kang, J, Hong, SM. Robust likelihood-based survival modeling with microarray data, J Stat Softw, 2009, 29, 1, 16",
            "process_entry": "True",
            "xmlid": "B23"
        },
        {
            "bibentry": "Jung, EJ, Lee, HJ, Kwak, C, Ku, JH, Moon, KC. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma, Urology, 2009, 73, 137, 141, PMID: 18950844",
            "process_entry": "True",
            "doi": "10.1016/j.urology.2008.08.460",
            "pmid": "18950844",
            "xmlid": "B24"
        },
        {
            "bibentry": "Ricketts, CJ, Linehan, WM. Gender specific mutation incidence and survival associations in Clear Cell Renal Cell Carcinoma (ccRCC), PLoS One, 2015, 10, e0140257, PMID: 26484545",
            "process_entry": "True",
            "doi": "10.1371/journal.pone.0140257",
            "pmid": "26484545",
            "pmcid": "PMC4618848",
            "xmlid": "B25"
        },
        {
            "bibentry": "Ebru, T, Fulya, OP, Hakan, A, Vuslat, YC, Necdet, S, Nuray, C. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma, Int Braz J Urol, 2017, 43, 440, 454, PMID: 27583351",
            "process_entry": "True",
            "doi": "10.1590/S1677-5538.IBJU.2015.0521",
            "pmid": "27583351",
            "pmcid": "PMC5462134",
            "xmlid": "B26"
        },
        {
            "bibentry": "Cheville, JC, Blute, ML, Zincke, H, Lohse, CM, Weaver, AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival, J Urol, 2001, 166, 453, 456, PMID: 11458046",
            "process_entry": "True",
            "doi": "10.1016/s0022-5347(05)65962-9",
            "pmid": "11458046",
            "xmlid": "B27"
        },
        {
            "bibentry": "Zhan, Y, Guo, W, Zhang, Y, Wang, Q, Xu, XJ, Zhu, L. A five-gene signature predicts prognosis in patients with kidney renal clear cell carcinoma, Comput Math Methods Med, 2015, 2015, 842784, PMID: 26539246",
            "process_entry": "True",
            "doi": "10.1155/2015/842784",
            "pmid": "26539246",
            "pmcid": "PMC4619904",
            "xmlid": "B28"
        },
        {
            "bibentry": "Liang, B, Zhao, J, Wang, X. A three-microRNA signature as a diagnostic and prognostic marker in clear cell renal cancer: an In Silico analysis, PLoS One, 2017, 12, e0180660, PMID: 28662155",
            "process_entry": "True",
            "doi": "10.1371/journal.pone.0180660",
            "pmid": "28662155",
            "pmcid": "PMC5491330",
            "xmlid": "B29"
        },
        {
            "bibentry": "Song, J, Peng, J, Zhu, C, Bai, G, Liu, Y, Zhu, J. Identification and validation of two novel prognostic lncRNAs in kidney renal clear cell carcinoma, Cell Physiol Biochem, 2018, 48, 2549, 2562, PMID: 30121668",
            "process_entry": "True",
            "doi": "10.1159/000492699",
            "pmid": "30121668",
            "xmlid": "B30"
        },
        {
            "bibentry": "Xu, D, Zhang, S, Zhang, S, Liu, H, Li, P, Yu, L. NOD2 maybe a biomarker for the survival of kidney cancer patients, Oncotarget, 2017, 8, 101489, 101499, PMID: 29254180",
            "process_entry": "True",
            "doi": "10.18632/oncotarget.21547",
            "pmid": "29254180",
            "pmcid": "PMC5731890",
            "xmlid": "B31"
        },
        {
            "bibentry": "Dai, W, Teodoridis, JM, Zeller, C, Graham, J, Hersey, J, Flanagan, JM. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival, Clin Cancer Res, 2011, 17, 4052, 4062, PMID: 21459799",
            "process_entry": "True",
            "doi": "10.1158/1078-0432.CCR-10-3021",
            "pmid": "21459799",
            "pmcid": "PMC3431504",
            "xmlid": "B32"
        },
        {
            "bibentry": "Zuo, S, Wang, L, Wen, Y, Dai, G. Identification of a universal 6-lncRNA prognostic signature for three pathologic subtypes of renal cell carcinoma, J Cell Biochem, 2018, 10, 30, [Epub]. Available at, DOI: 10.1002/jcb.28012",
            "process_entry": "True",
            "doi": "10.1002/jcb.28012",
            "xmlid": "B33"
        },
        {
            "bibentry": "Wu, F, Kaczynski, TJ, Sethuramanujam, S, Li, R, Jain, V, Slaughter, M. Two transcription factors, Pou4f2 and Isl1, are sufficient to specify the retinal ganglion cell fate, Proc Natl Acad Sci U S A, 2015, 112, E1559, E1568, PMID: 25775587",
            "process_entry": "True",
            "doi": "10.1073/pnas.1421535112",
            "pmid": "25775587",
            "pmcid": "PMC4386335",
            "xmlid": "B34"
        },
        {
            "bibentry": "Maskell, LJ, Mahadeo, AV, Budhram-Mahadeo, VS. POU4F2/Brn-3b transcription factor is associated with survival and drug resistance in human ovarian cancer cells, Oncotarget, 2018, 9, 36770, 36779, PMID: 30613365",
            "process_entry": "True",
            "doi": "10.18632/oncotarget.26371",
            "pmid": "30613365",
            "pmcid": "PMC6298405",
            "xmlid": "B35"
        },
        {
            "bibentry": "Reinert, T, Borre, M, Christiansen, A, Hermann, GG, Ørntoft, TF, Dyrskjøt, L. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation, PLoS One, 2012, 7, e46297, PMID: 23056278",
            "process_entry": "True",
            "doi": "10.1371/journal.pone.0046297",
            "pmid": "23056278",
            "pmcid": "PMC3463582",
            "xmlid": "B36"
        },
        {
            "bibentry": "Christie, JD, Ma, SF, Aplenc, R, Li, M, Lanken, PN, Shah, CV. Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma, Crit Care Med, 2008, 36, 2794, 2800, PMID: 18828194",
            "process_entry": "True",
            "doi": "10.1097/ccm.0b013e318186b843",
            "pmid": "18828194",
            "xmlid": "B37"
        },
        {
            "bibentry": "Soung, YH, Lee, JW, Kim, SY, Nam, SW, Park, WS, Lee, JY. Mutational analysis of the kinase domain of MYLK2 gene in common human cancers, Pathol Res Pract, 2006, 202, 137, 140, PMID: 16448786",
            "process_entry": "True",
            "doi": "10.1016/j.prp.2005.12.003",
            "pmid": "16448786",
            "xmlid": "B38"
        }
    ],
    "localid": "MED-31637882",
    "doi": "10.3349/ymj.2019.60.11.1013",
    "pmid": "10.3349/ymj.2019.60.11.1013",
    "pmcid": "31637882",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31637882/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "B1",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,707)",
                "containers_title": [
                    "INTRODUCTION"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "B8",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,601)",
                "containers_title": [
                    "INTRODUCTION"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "B12",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),603,302)",
                "containers_title": [
                    "INTRODUCTION"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "B14",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),906,603)",
                "containers_title": [
                    "INTRODUCTION"
                ],
                "pl_string": "Important targets in cancer research, cancer initiation and proliferation are regulated by epigenetic modifications.8 As one of the basic mechanism of epigenetic modification, DNA methylation plays as a pivotal role in the processes of chromatin structure regulation and gene regulation.9 Abnormal DNA methylation was reported to show a significant relationship with the occurrence and prognosis of various cancers.10 Dubrowinskaja, et al.11 demonstrated that neurofilament heavy (NEFH)-specific hypermethylation in RCC is relevant to overall survival rates among patients undergoing targeted therapy. Mir-874, which is downregulated in breast cancer, is correlated with the prognosis of breast cancer.12 Zhang, et al.13 demonstrated that decreased of mir-874 expression is mediated by DNA methylation of the promoter region and that DNA methylation is directly related to the prognosis of breast cancer. Furthermore, DNA methylation of specific genes has already been used as biomarkers in early diagnosis and prognosis,14,15 such as aldehyde dehydrogenase 1 family member A3 (ALDH1A3) promoter hypermethylation in glioma CpG island methylator phenotype-primary glioblastoma16 and hypomethylation of cyclin dependent kinase inhibitor 2A (CDKN2A) in colon cancer.17 Moreover, for patients with stage I non-small cell lung cancer, a shorter relapse-free survival rate has been found to be associated with higher methylation levels of CpG sites within five genes (HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9).18",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 4,
                "xref_id": "B15",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),906,603)",
                "containers_title": [
                    "INTRODUCTION"
                ],
                "pl_string": "Important targets in cancer research, cancer initiation and proliferation are regulated by epigenetic modifications.8 As one of the basic mechanism of epigenetic modification, DNA methylation plays as a pivotal role in the processes of chromatin structure regulation and gene regulation.9 Abnormal DNA methylation was reported to show a significant relationship with the occurrence and prognosis of various cancers.10 Dubrowinskaja, et al.11 demonstrated that neurofilament heavy (NEFH)-specific hypermethylation in RCC is relevant to overall survival rates among patients undergoing targeted therapy. Mir-874, which is downregulated in breast cancer, is correlated with the prognosis of breast cancer.12 Zhang, et al.13 demonstrated that decreased of mir-874 expression is mediated by DNA methylation of the promoter region and that DNA methylation is directly related to the prognosis of breast cancer. Furthermore, DNA methylation of specific genes has already been used as biomarkers in early diagnosis and prognosis,14,15 such as aldehyde dehydrogenase 1 family member A3 (ALDH1A3) promoter hypermethylation in glioma CpG island methylator phenotype-primary glioblastoma16 and hypomethylation of cyclin dependent kinase inhibitor 2A (CDKN2A) in colon cancer.17 Moreover, for patients with stage I non-small cell lung cancer, a shorter relapse-free survival rate has been found to be associated with higher methylation levels of CpG sites within five genes (HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9).18",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 5,
                "xref_id": "B16",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),906,603)",
                "containers_title": [
                    "INTRODUCTION"
                ],
                "pl_string": "Important targets in cancer research, cancer initiation and proliferation are regulated by epigenetic modifications.8 As one of the basic mechanism of epigenetic modification, DNA methylation plays as a pivotal role in the processes of chromatin structure regulation and gene regulation.9 Abnormal DNA methylation was reported to show a significant relationship with the occurrence and prognosis of various cancers.10 Dubrowinskaja, et al.11 demonstrated that neurofilament heavy (NEFH)-specific hypermethylation in RCC is relevant to overall survival rates among patients undergoing targeted therapy. Mir-874, which is downregulated in breast cancer, is correlated with the prognosis of breast cancer.12 Zhang, et al.13 demonstrated that decreased of mir-874 expression is mediated by DNA methylation of the promoter region and that DNA methylation is directly related to the prognosis of breast cancer. Furthermore, DNA methylation of specific genes has already been used as biomarkers in early diagnosis and prognosis,14,15 such as aldehyde dehydrogenase 1 family member A3 (ALDH1A3) promoter hypermethylation in glioma CpG island methylator phenotype-primary glioblastoma16 and hypomethylation of cyclin dependent kinase inhibitor 2A (CDKN2A) in colon cancer.17 Moreover, for patients with stage I non-small cell lung cancer, a shorter relapse-free survival rate has been found to be associated with higher methylation levels of CpG sites within five genes (HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9).18",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 6,
                "xref_id": "B17",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),906,603)",
                "containers_title": [
                    "INTRODUCTION"
                ],
                "pl_string": "Important targets in cancer research, cancer initiation and proliferation are regulated by epigenetic modifications.8 As one of the basic mechanism of epigenetic modification, DNA methylation plays as a pivotal role in the processes of chromatin structure regulation and gene regulation.9 Abnormal DNA methylation was reported to show a significant relationship with the occurrence and prognosis of various cancers.10 Dubrowinskaja, et al.11 demonstrated that neurofilament heavy (NEFH)-specific hypermethylation in RCC is relevant to overall survival rates among patients undergoing targeted therapy. Mir-874, which is downregulated in breast cancer, is correlated with the prognosis of breast cancer.12 Zhang, et al.13 demonstrated that decreased of mir-874 expression is mediated by DNA methylation of the promoter region and that DNA methylation is directly related to the prognosis of breast cancer. Furthermore, DNA methylation of specific genes has already been used as biomarkers in early diagnosis and prognosis,14,15 such as aldehyde dehydrogenase 1 family member A3 (ALDH1A3) promoter hypermethylation in glioma CpG island methylator phenotype-primary glioblastoma16 and hypomethylation of cyclin dependent kinase inhibitor 2A (CDKN2A) in colon cancer.17 Moreover, for patients with stage I non-small cell lung cancer, a shorter relapse-free survival rate has been found to be associated with higher methylation levels of CpG sites within five genes (HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9).18",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 7,
                "xref_id": "B18",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[11]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),906,603)",
                "containers_title": [
                    "INTRODUCTION"
                ],
                "pl_string": "Important targets in cancer research, cancer initiation and proliferation are regulated by epigenetic modifications.8 As one of the basic mechanism of epigenetic modification, DNA methylation plays as a pivotal role in the processes of chromatin structure regulation and gene regulation.9 Abnormal DNA methylation was reported to show a significant relationship with the occurrence and prognosis of various cancers.10 Dubrowinskaja, et al.11 demonstrated that neurofilament heavy (NEFH)-specific hypermethylation in RCC is relevant to overall survival rates among patients undergoing targeted therapy. Mir-874, which is downregulated in breast cancer, is correlated with the prognosis of breast cancer.12 Zhang, et al.13 demonstrated that decreased of mir-874 expression is mediated by DNA methylation of the promoter region and that DNA methylation is directly related to the prognosis of breast cancer. Furthermore, DNA methylation of specific genes has already been used as biomarkers in early diagnosis and prognosis,14,15 such as aldehyde dehydrogenase 1 family member A3 (ALDH1A3) promoter hypermethylation in glioma CpG island methylator phenotype-primary glioblastoma16 and hypomethylation of cyclin dependent kinase inhibitor 2A (CDKN2A) in colon cancer.17 Moreover, for patients with stage I non-small cell lung cancer, a shorter relapse-free survival rate has been found to be associated with higher methylation levels of CpG sites within five genes (HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9).18",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 8,
                "xref_id": "B19",
                "rp_string": "19",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,195)",
                "containers_title": [
                    "INTRODUCTION"
                ]
            }
        ],
        [
            {
                "n_rp": 9,
                "xref_id": "B21",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[2]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[1]/p),740,311)",
                "containers_title": [
                    "MATERIALS AND METHODS",
                    "DNA methylation information for ccRCC tissues in the TCGA dataset"
                ]
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "B23",
                "rp_string": "23",
                "rp_xpath": "/article/body/sec[2]/sec[2]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/p),349,145)",
                "containers_title": [
                    "MATERIALS AND METHODS",
                    "Prognostic identification and choosing CpG sites"
                ]
            }
        ],
        [
            {
                "n_rp": 11,
                "xref_id": "B24",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[3]/sec[4]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[4]/p),1,131)",
                "containers_title": [
                    "RESULTS",
                    "Predictive performance of the two-DNA methylation signature"
                ]
            }
        ],
        [
            {
                "n_rp": 12,
                "xref_id": "B25",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[3]/sec[4]/p/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[4]/p),945,87)",
                "containers_title": [
                    "RESULTS",
                    "Predictive performance of the two-DNA methylation signature"
                ]
            }
        ],
        [
            {
                "n_rp": 13,
                "xref_id": "B28",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[4]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[1]),102,455)",
                "containers_title": [
                    "DISCUSSION"
                ]
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "B28",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[4]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[2]),188,105)",
                "containers_title": [
                    "DISCUSSION"
                ]
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "B33",
                "rp_string": "33",
                "rp_xpath": "/article/body/sec[4]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[2]),294,128)",
                "containers_title": [
                    "DISCUSSION"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "B34",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[4]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[3]),295,449)",
                "containers_title": [
                    "DISCUSSION"
                ]
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "B35",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[4]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[3]),745,653)",
                "containers_title": [
                    "DISCUSSION"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "B37",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[4]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[3]),1399,319)",
                "containers_title": [
                    "DISCUSSION"
                ]
            }
        ]
    ]
}